Drugs / TmCD19-IL18
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05989204 | Nov 2023 → Oct 2026 expected | non-Hodgkin lymphoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TmCD19-IL18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05989204 ↗ |
| Modality | Cell therapy | “autologous Chimeric Antigen Receptor (CAR) T cells” NCT05989204 ↗ |
| Route | Intravenous | “administered as a single intravenous (IV) infusion” NCT05989204 ↗ |
| Target | CD19 | “directed against the human CD19 antigen” NCT05989204 ↗ |